Aquestive Therapeutics, Inc. (AQST) financial statements and ratios from SEC XBRL: revenue $44.55M (TTM), net margin -188.1%, revenue growth -22.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $44.55M |
| Net Margin | -188.1% |
| Revenue Growth (YoY) | -22.6% |
| EPS Growth (YoY) | 52.9% |
| FCF Growth (YoY) | 47.5% |
| Price / Sales | 10.51 |
| FCF Yield | -16.9% |
| Altman Z-Score | -2.57 (distress) |
| Piotroski F-Score | 2/9 |
| Sector P/E (Healthcare) | 21.7 |
AQST overview · AQST earnings · AQST KPIs · AQST investor relations · AQST ownership · AQST peers · AQST filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.